Evidence Explorer · MS-N236 · Traditional Chinese 12-herb formula · Supportive care · Appraised November 4, 2026
A phase II randomized trial reported a larger six-week fatigue reduction with Renshen Yangrong Tang than with low-dose huangqi. The active comparator and single study limit certainty.
Evidence at a glance
Benefit signal: Promising short-term fatigue response
Certainty: Low to very low; 83 evaluable participants, active control and no independent replication
Risk context: No grade 3–4 toxicity reported, but multi-herb interactions and long-term safety remain uncertain
What was studied
Cancer survivors with fatigue rated at least 4/10 for more than two months received Renshen Yangrong Tang extract granules or low-dose huangqi twice daily for six weeks. Eighty-three people were evaluable: 41 intervention and 42 control.
At week 4, mean fatigue-severity change was −2.66 versus −1.36 (Cohen d=1.0; P<.0001). A two-point fatigue reduction occurred in 90.2% versus 52.4%.
What this evidence cannot establish
The comparator was an active herb rather than inert placebo, and the heterogeneous survivor population limits disease-specific interpretation. Durability beyond six weeks is unknown.
Fatigue response does not establish tumor control or improved survival. Different commercial formulas may not reproduce the tested 12-herb extract.
Practical safety context
No discomfort or grade 3–4 toxicity was reported, but the trial was too small and short to establish uncommon, cumulative or interaction harms. Ginseng-, Astragalus- and licorice-containing formulas may affect blood pressure, potassium, glucose, bleeding or drug metabolism.
Persistent fatigue requires evaluation for reversible medical and psychosocial causes before adding a multi-herb product.
Questions for the care team
- Is the exact 12-herb formulation and manufacturing standard available?
- Could any component interact with anticoagulants, endocrine therapy or immunotherapy?
- How will fatigue, blood pressure, electrolytes and liver tests be monitored?
- What evidence-based exercise, sleep or psychological options are available?
Funding and conflicts
The study reported non-U.S. government research support. Detailed commercial involvement was not verified from the accessible abstract.
Sources
- Phase II randomized trial (PMID 31668965)
- 2026 systematic review of oral herbal preparations in supportive cancer care (PMID 42930516)
Sources and publication status checked November 4, 2026. Last literature search: November 4, 2026; record appraisal: November 4, 2026.
For education, not personal medical advice. Research regimens are not personal prescriptions. Symptom, laboratory or biomarker changes do not establish tumor response, recurrence prevention or longer survival.
